Roche flags 2023 earnings decline on slump in COVID products Ruchika Sharma3 Feb 2023 5:51 AM GMTAnalysts have said that market confidence in Roche's drug development abilities, previously among the highest in the industry, has taken a blow from...
Casirivimab/Imdevimab - An Indian Real World Experience : Review Dr. Kamal Kant Kohli10 Jun 2022 6:19 AM GMTThe antibody cocktail (Casirivimab and Imdevimab) has been approved in India for the treatment of mild to moderate COVID-19 in adolescents and adults...
Review: Efficacy of Antiviral Agents Against Omicron Subvariant BA.2 Dr. Kamal Kant Kohli16 May 2022 6:15 AM GMTThe omicron (B.1.1.529) variant of SARS-CoV-2, has spread rapidly around the world and has already become the predominant variant circulating in many...
Review: Casirivimab-Imdevimab antibody Cocktail in Patients Amidst and Post COVID-19 Treatment Dr. Kamal Kant Kohli28 March 2022 6:45 AM GMTCasirivimab and Imdevimab are two IgG1 anti-SARS-CoV-2 monoclonal antibodies, given emergency use authorization by the US FDA, European Medical...
Decoding REGEN-COV2 for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients Dr. Kamal Kant Kohli17 March 2022 6:15 AM GMTKidney transplant recipients are an immunocompromised population, with comorbid conditions such as obesity, diabetes, and coronary artery disease,...
Casirivimab and imdevimab in patients admitted to hospital with COVID-19: RECOVERY Trial Dr. Kamal Kant Kohli9 March 2022 11:49 AM GMTCasirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor-binding domain of the SARS-CoV-2...
Quick Review: Effectiveness of REGEN-COV antibody cocktail against B.1.617.2 (delta) variant of SARS-CoV-2 Dr. Kamal Kant Kohli1 Feb 2022 7:04 AM GMTCasirivimab plus imdevimab antibody cocktail (REGEN-COV) has been shown to reduce viral load and prevent symptomatic disease in household contacts of...
Understanding Monoclonal Antibody in Treatment of Hospitalized Patients with COVID-19 Dr. Kamal Kant Kohli18 Jan 2022 7:15 AM GMTHospitalized COVID-19 patients reported having high mortality rates (10-30%). Casirivimab and imdevimab antibody cocktail (REGEN-COV®) are authorized...
NIH guidelines recommend the use of Casirivimab plus Imdevimab for post-exposure prophylaxis of COVID-19 Dr. Kamal Kant Kohli16 Nov 2021 7:27 AM GMTWhile Vaccine remains the mainstay of protection against Coronavirus Disease 2019 (COVID-19), a recent update from the National Institute of Health...
Japanese nod to Ronapreve (casirivimab and imdevimab) for treatment of mild to moderate Covid-19 Ruchika Sharma20 July 2021 5:00 AM GMTBasel: Pharma major, Roche, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve (casirivimab and...
